You are here:

alectinib hydrochloride (Alecensa)

Advice

in the absence of a submission from the holder of the marketing authorisation:

alectinib hydrochloride (Alecensa®) is not recommended for use within NHS Scotland.

Indication under review: As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer previously treated with crizotinib.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: alectinib hydrochloride (Alecensa)
SMC Drug ID: 1257/17
Manufacturer: Roche
Indication: As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer previously treated with crizotinib.
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 8 May 2017

Back